P: (541) 388-2333
F: 833-450-5235
1140 SW Simpson Ave Ste 100, Bend, OR 97702
info@hdssbend.com
REQUEST APPOINTMENT
PATIENT PORTAL
P: 541-388-2333
F: 833-450-5235
1140 SW Simpson Ave, Suite 100, Bend, OR 97702
info@HDSSBend.com
REQUEST APPOINTMENT
PATIENT PORTAL
High Desert Sports & Spine Clinic Bend, OR

Clinical Research Library

Our clinical protocols are rooted in evidence-based medicine. We utilize peer-reviewed data to guide our patient selection and treatment strategies, focusing on the safety, functional outcomes, and biological mechanisms of orthobiologic therapies.

Table Of Contents

Bone Marrow Aspirate Concentrate (BMAC) Clinical Research

Sentinel & Long-Term Studies

  • Hernigou et al. (2021) — Subchondral vs. Intra-Articular BMAC: 15-Year Randomized Study in Knee OA

This landmark 15-year randomized study treated 60 patients with arthritis in both knees — one knee received stem cells injected directly into the bone beneath the cartilage (subchondral), while the other received the same cells injected into the joint; at 15 years, only 20% of the subchondral-treated knees needed a knee replacement compared to 70% of the joint-injected knees. This is the longest follow-up study of its kind and strongly suggests that delivering stem cells into the bone is far more effective than injecting them into the joint alone. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32617651

  • Hernigou et al. (2021) — Subchondral BMAC vs. Contralateral Knee Replacement: 15-Year Follow-Up in 140 Patients

In this large study of 140 elderly patients (average age 75) scheduled for bilateral knee replacement, one knee received the replacement while the other received stem cells injected into the subchondral bone instead; at 15 years, only 18% of the stem cell-treated knees eventually needed a knee replacement — a rate comparable to the revision rate of the knee replacements themselves. The study showed that bone marrow lesions (swelling in the bone) larger than 3 cm that did not shrink after treatment were the strongest predictor of eventually needing surgery. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32322943

  •  Hernigou et al. (2018) — Subchondral BMAC vs. Knee Replacement in Young Patients with Osteonecrosis This randomized trial studied 30 young patients (average age 28) with severe knee arthritis caused by steroid-related bone death (osteonecrosis) in both knees — one knee received a knee replacement and the other received subchondral stem cell injection; at 12 years, only 1 stem cell-treated knee needed further surgery compared to 6 knee replacements that required revision, and 21 of 30 patients preferred the stem cell-treated knee. The study demonstrated that subchondral BMAC had fewer complications, faster recovery, and comparable functional outcomes to knee replacement in this challenging young patient population. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/29589086
  • Pearl et al. (2023) — BMAC Chondroplasty with Intraosseous Injection to Delay Knee Replacement
    • In this study of veterans with knee arthritis, BMAC was applied both into the joint and into the bone during a minor surgical procedure; only 22% of patients required any further intervention within 2 years, and only one patient requested a knee replacement. These results suggest that BMAC chondroplasty may help delay or avoid the need for knee replacement surgery. 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37994424

Anz et al. (2022) — BMAC vs. PRP Randomized Trial for Knee OA

This randomized trial of 90 patients found that a single BMAC injection improved knee pain and function for up to 2 years, performing equally well as platelet-rich plasma (PRP). Both treatments provided meaningful and sustained relief, with improvements plateauing at 3 months and lasting through 24 months. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35289231

 Keeling et al. (2022) — Systematic Review of BMAC for Knee OA

This review of 8 studies and 299 knees found that BMAC injections significantly improved pain and function in over 94% of measured outcomes, though BMAC was not proven superior to other biologic treatments like PRP. The findings support BMAC as an effective option for knee arthritis symptom relief. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34236913

Belk et al. (2023) — Meta-Analysis: PRP/BMAC vs. Hyaluronic Acid for Knee OA

This large meta-analysis of 27 Level I studies found that patients receiving BMAC or PRP injections experienced significantly better pain relief and function compared to those receiving hyaluronic acid (gel) injections. BMAC and PRP performed similarly to each other, but both outperformed traditional gel injections. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36913992

 Pabinger et al. (2024) — 4-Year Results of BMAC for Severe Knee OA

In patients with severe knee arthritis (Kellgren-Lawrence grade III–IV), a single BMAC injection led to significant improvements in pain, function, and walking distance sustained over 4 years, with a 95% success rate and no patients requiring knee replacement. This is one of the longest follow-up studies for BMAC in advanced arthritis. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38302491

  1. Manchikanti et al. (2020) — ASIPP Evidence-Based Position Statement on BMAC

This comprehensive review by the American Society of Interventional Pain Physicians found the strongest evidence (Level II) for BMAC in knee osteoarthritis, with emerging evidence across multiple musculoskeletal conditions, and confirmed strong evidence for the safety of BMAC when performed by trained physicians. The statement supports BMAC as meeting FDA criteria for minimal manipulation and homologous use in musculoskeletal care. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32214287

TENDINOPATHY

  1. Pascual-Garrido et al. (2012) — 5-Year Follow-Up of Bone Marrow Stem Cells for Patellar Tendinopathy

This early study treated patients with chronic patellar (kneecap) tendon pain using bone marrow-derived cells and found significant improvements in pain and function that were maintained for 5 years. It was one of the first studies to demonstrate long-term durability of stem cell treatment for tendon problems. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/22220180

  1. Rodas et al. (2021) — Bone Marrow Stem Cells vs. PRP for Patellar Tendinopathy

This double-blind randomized trial found that both bone marrow stem cells and PRP reduced pain and improved activity levels in athletes with chronic patellar tendon problems, but patients receiving stem cells showed significantly greater improvement in tendon structure on MRI and ultrasound. The study suggests stem cells may promote better tendon healing compared to PRP alone. 

 🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33783227

  1. Thueakthong et al. (2021) — BMAC for Recalcitrant Achilles Tendinopathy

Patients with chronic Achilles tendon pain that had not responded to other treatments received a BMAC injection and experienced significant pain reduction that continued to improve over 48 weeks, with no complications. This study suggests BMAC may be a safe and effective option for stubborn Achilles tendon problems that have failed other treatments. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34254148

PARTIAL ROTATOR CUFF TEARS — BMAC & PRP

 Kim et al. (2017) — Effects of BMAC-PRP on Tendon-Derived Stem Cells and Rotator Cuff Tendon Tear

This study investigated the effects of ultrasound-guided BMAC-PRP injections at the tear site in patients with partial rotator cuff tears and found that ASES scores improved significantly from 39.4 at baseline to 71.8 at 3 months (p < 0.01), with pain scores also decreasing significantly, while MRI showed visible reduction in tear size at 3 months. The laboratory component of the study also demonstrated that BMAC-PRP enhanced stem cell proliferation and migration while preventing abnormal cell differentiation, providing a mechanistic basis for the clinical improvements observed. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/28105983

LONG-TERM SAFETY & EFFICACY — PARTIAL ROTATOR CUFF TEARS

 Centeno et al. (2024) — Percutaneous BMC and Platelet Products vs. Exercise Therapy for Rotator Cuff Tears: 2-Year Follow-Up

This randomized controlled trial found that patients with partial or full-thickness rotator cuff tears who received percutaneous BMAC and platelet product injections had significantly greater improvements in pain, function (DASH), and overall satisfaction compared to exercise therapy alone, with benefits sustained through 2 years and no serious adverse events. A majority of treated patients (73%) showed MRI evidence of tendon healing, and over 90% achieved clinically meaningful improvement by 12 months. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38762734

Appointments and Questions

PRP Clinical Research

KNEE OSTEOARTHRITIS

  1. Bensa et al. (2025) — Meta-Analysis of 18 RCTs: PRP vs. Placebo for Knee OA (1,995 Patients)

This large meta-analysis of 18 randomized controlled trials found that PRP injections provided clinically meaningful improvements in both pain and function compared to placebo at 1, 3, 6, and 12 months, with pain relief exceeding the threshold patients can actually feel at 3 and 6 months. Importantly, the study found that high-platelet PRP provided superior and longer-lasting results than low-platelet PRP, suggesting that the concentration of platelets in the injection matters for treatment success. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39751394

  1. Jawanda et al. (2024) — Network Meta-Analysis of 48 RCTs: PRP, BMAC, HA, and Corticosteroid for Knee OA (9,338 Knees)

This massive network meta-analysis of 48 randomized trials and over 9,300 knees found that PRP ranked as the most effective injection for both pain relief and functional improvement at 6+ months, outperforming bone marrow concentrate, hyaluronic acid, corticosteroid, and placebo. The study confirmed that corticosteroid injections ranked last among all biologic options, performing no better than placebo at 6 months. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38331363

  1. Singh et al. (2022) — Network Meta-Analysis of RCTs: Relative Efficacy of Knee OA Injections

This network meta-analysis of randomized controlled trials found that PRP had the highest probability of being the most effective injection for both pain and function in knee osteoarthritis at 6+ months, followed by plasma rich in growth factors (PRGF), hyaluronic acid, and corticosteroid — with corticosteroid performing no better than placebo. PRP was the only injection to demonstrate a clinically meaningful difference in function compared to both corticosteroid and placebo. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34403285

  1. Bennell et al. (2021) — RESTORE Trial: PRP vs. Placebo for Knee OA (JAMA, 288 Patients)

This rigorous, double-blind randomized trial published in JAMA found that three weekly injections of leukocyte-poor PRP did not result in a significant difference in knee pain or cartilage volume compared to saline placebo at 12 months in patients with mild-to-moderate knee osteoarthritis. This is one of the highest-quality individual trials and highlights that not all PRP formulations may be equally effective — the study used a low-platelet, leukocyte-poor preparation that subsequent meta-analyses have shown may be less effective than high-platelet formulations. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34812863

  1. Johal et al. (2019) — Largest Meta-Analysis: PRP Across All Orthopedic Conditions (78 RCTs, 5,308 Patients)

This is the largest meta-analysis of PRP in orthopedics, including 78 randomized controlled trials and over 5,300 patients across multiple conditions; it found that PRP reduced pain at 3 months with benefits increasing and becoming clinically significant by 1 year. The strongest evidence for clinically meaningful pain relief was found for lateral epicondylitis (tennis elbow) and knee osteoarthritis. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31136726

  1. Qiao et al. (2023) — Network Meta-Analysis: PRP, PRP+HA, HA, and Corticosteroid for Knee OA (35 RCTs)

This network meta-analysis of 35 randomized trials found that PRP and PRP combined with hyaluronic acid were the most effective treatments for improving both pain and function at 3, 6, and 12 months, and that none of the treatments — including PRP — increased the risk of side effects compared to placebo. The combination of PRP + HA showed particular promise for pain relief, suggesting that combining these two treatments may offer additional benefit. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38037038

HIP OSTEOARTHRITIS

  1. Dallari et al. (2016) — Level I RCT: PRP vs. HA vs. PRP+HA for Hip OA (111 Patients)

This Level I randomized controlled trial of 111 patients found that PRP injections provided significantly better pain relief than both hyaluronic acid and PRP+HA combination at 6 months, with the benefit remaining more stable through 12 months than either comparator. Interestingly, adding hyaluronic acid to PRP did not improve outcomes — PRP alone was the most effective treatment. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/26797697

  1. Lim et al. (2023) — First Systematic Review & Meta-Analysis: PRP for Hip OA (331 Patients)

This first-of-its-kind systematic review of PRP for hip osteoarthritis found that PRP significantly reduced pain compared to baseline, with the greatest effect at 1–2 months, and that a single injection of leukocyte-poor PRP at a dose under 15 mL produced the best results. The study provides early evidence that PRP may help patients with hip arthritis who are too early for hip replacement but not responding to other conservative treatments. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35971803

ROTATOR CUFF — INJECTION FOR TENDINOPATHY & PARTIAL TEARS

  1. Yuwarungsikul et al. (2026) — Meta-Analysis of 10 RCTs: PRP vs. Corticosteroid for Rotator Cuff Tendinopathy

This meta-analysis of 10 randomized controlled trials (591 patients) found that PRP injections provided significantly better shoulder function scores (ASES +10.8 points, Constant-Murley +10.7 points) and pain relief compared to corticosteroid injections at 6 months, with fewer adverse events. While corticosteroid provided faster initial relief, PRP offered more durable improvement, supporting its use as a longer-lasting alternative for rotator cuff tendinopathy. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42021740

  1. Kwong et al. (2021) — Double-Blind RCT: PRP vs. Corticosteroid for Partial Rotator Cuff Tears (99 Patients)

This double-blind randomized trial of 99 patients found that PRP injection produced significantly greater improvement in pain, shoulder function (ASES), and quality of life (WORC) scores at 3 months compared to corticosteroid injection for partial-thickness rotator cuff tears and tendinopathy. While both treatments improved symptoms, PRP provided superior short-term results, though the difference was not sustained at 12 months. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33127554

ROTATOR CUFF — PRP AUGMENTATION OF SURGICAL REPAIR

  1. Chen et al. (2020) — Meta-Analysis of 18 Level I Studies: PRP for Rotator Cuff Tears (1,116 Patients)

This meta-analysis exclusively of Level I randomized trials found that PRP significantly reduced long-term retear rates by 66% (OR 0.34) in patients undergoing rotator cuff repair, with the benefit seen regardless of whether leukocyte-rich or leukocyte-poor PRP was used. The study also found that PRP was particularly effective in patients with multiple tendon tears, where retear rates were reduced by 72%. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31743037

  1. Dunivan et al. (2026) — Meta-Analysis: LP-PRP Reduces Retear Risk After Rotator Cuff Repair (21 Studies, 1,279 Patients)

This comprehensive meta-analysis found that leukocyte-poor PRP (LP-PRP) augmentation during arthroscopic rotator cuff repair reduced structural retear rates by approximately 46%, with the most consistent benefit in medium-sized tears. An economic analysis showed that LP-PRP may achieve cost neutrality or modest savings by reducing the need for costly revision surgeries. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41759819

  1. Hovland et al. (2025) — Meta-Analysis of 9 RCTs: LP-PRP in Rotator Cuff Repair (743 Patients)

This meta-analysis of 9 randomized controlled trials found that leukocyte-poor PRP reduced retear rates by 46% compared to controls (risk ratio 0.54, p < .00001), with significantly improved pain, ASES, Constant, and UCLA scores — though the clinical outcome improvements did not meet the minimal clinically important difference. The primary benefit of LP-PRP is enhancing structural tendon healing rather than improving symptoms. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40409437

LATERAL EPICONDYLITIS (TENNIS ELBOW)

  1. Lhee et al. (2025) — RCT: PRP vs. Prolotherapy vs. Shockwave vs. Physiotherapy for Chronic Tennis Elbow (231 Patients, 2-Year Follow-Up)

This large randomized trial of 231 patients found that PRP produced the greatest improvement in arm function (DASH score reduction of 31 points) and highest patient satisfaction at 2 years compared to prolotherapy, shockwave therapy, and physiotherapy alone. PRP and prolotherapy both significantly outperformed shockwave and physiotherapy, supporting their use as effective non-surgical options for chronic tennis elbow that has not responded to initial treatment. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40815854

  1. Xu et al. (2024) — Meta-Analysis of 11 RCTs: PRP vs. Corticosteroid for Lateral Epicondylitis (730 Patients)

This meta-analysis found that while corticosteroid injections provided faster pain relief in the first 2 months, PRP delivered significantly better long-term pain relief and functional improvement at 6+ months for tennis elbow. The study highlights the classic trade-off: corticosteroid works faster but fades, while PRP takes longer to work but provides more durable results. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38357713

  1. Antunes Júnior et al. (2026) — Meta-Analysis of 6 RCTs: PRP vs. Placebo for Lateral Epicondylitis (355 Patients)

This recent meta-analysis comparing PRP specifically to placebo (rather than corticosteroid) found no significant benefit of PRP over placebo for pain or function at any time point (4, 8–12, or 24–26 weeks) in patients with tennis elbow. This contrasting finding highlights that while PRP may outperform corticosteroid long-term, its superiority over placebo alone remains unproven for this condition. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41508659

PLANTAR FASCIITIS

  1. Peerbooms et al. (2019) — Level I Double-Blind Multicenter RCT: PRP vs. Corticosteroid for Plantar Fasciitis (115 Patients)

This double-blind multicenter randomized trial found that while corticosteroid injection provided faster initial pain relief, PRP produced significantly greater pain reduction and functional improvement at 1 year, with 84% of PRP patients achieving at least 25% improvement compared to only 56% in the corticosteroid group. The study demonstrates that PRP provides more durable relief for chronic plantar fasciitis than corticosteroid injection. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31603721

  1. Hohmann et al. (2021) — Meta-Analysis of 15 RCTs: PRP vs. Corticosteroid for Plantar Fasciitis

This meta-analysis of 15 randomized trials found that PRP was superior to corticosteroid for pain control starting at 3 months and lasting through 12 months, with no advantage for corticosteroid even in the short term. The study supports PRP as a first-line injection option for chronic plantar fasciitis, though the authors note that low study quality warrants cautious interpretation. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/32822236

GLUTEAL TENDINOPATHY / GREATER TROCHANTERIC PAIN SYNDROME

  1. Fitzpatrick et al. (2019) — Level I Double-Blind RCT: PRP vs. Corticosteroid for Gluteal Tendinopathy (80 Patients, 2-Year Follow-Up)

This double-blind randomized trial found that a single PRP injection produced significantly greater and more sustained improvement in hip pain and function than corticosteroid injection, with benefits continuing to improve through 2 years (baseline mHHS 53.8 → 82.6 at 2 years). Notably, 27 patients who failed corticosteroid treatment were crossed over to PRP and experienced significant improvement, further supporting PRP’s superiority for this condition. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/30840831

  1. Atchia et al. (2025) — Double-Blind RCT: PRP vs. Placebo for Greater Trochanteric Pain Syndrome (79 Patients)

This rigorous double-blind trial found no significant difference between PRP and placebo injection for greater trochanteric pain syndrome at any follow-up point through 12 months, with both groups showing improvement from baseline. This contrasting result to the Fitzpatrick trial highlights that PRP’s benefit for this condition may depend on the specific formulation and injection technique used. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39804899

ACHILLES TENDINOPATHY

  1. Kearney et al. (2021) — JAMA Multicenter RCT: PRP vs. Sham Injection for Achilles Tendinopathy (240 Patients)

This large, multicenter randomized trial published in JAMA found that a single PRP injection was no more effective than a sham (dry needle) injection for chronic midportion Achilles tendinopathy at 6 months, with both groups showing similar modest improvement. This is one of the highest-quality trials in the field and does not support the use of PRP for this specific condition. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/34228062

  1. Barreto et al. (2025) — Meta-Analysis of 6 RCTs: PRP for Achilles Tendinopathy (422 Patients)

This meta-analysis confirmed that PRP does not improve pain or function compared to placebo at 3, 6, or 12 months for Achilles tendinopathy, and noted that publication bias may have inflated the apparent benefits seen in earlier studies. The authors conclude that PRP should not be used for Achilles tendinopathy until future high-quality trials demonstrate a clear benefit. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39745256

PATELLAR TENDINOPATHY (JUMPER’S KNEE)

  1. Andriolo et al. (2019) — Systematic Review & Meta-Analysis of 70 Studies: Nonsurgical Treatments for Patellar Tendinopathy (2,530 Patients)

This comprehensive review of 2,530 patients found that while eccentric exercises provided the best short-term results, multiple PRP injections produced the best long-term outcomes (≥6 months) for patellar tendinopathy, outperforming shockwave therapy and exercise alone. The study supports a treatment approach of starting with exercise therapy and considering multiple PRP injections for patients who do not improve. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/29601207

  1. Scott et al. (2019) — Level I RCT: LR-PRP vs. LP-PRP vs. Saline for Patellar Tendinopathy (57 Patients)

This Level I randomized trial found that neither leukocyte-rich nor leukocyte-poor PRP was more effective than saline injection when combined with a structured rehabilitation program for patellar tendinopathy at any time point through 12 months. The study suggests that the exercise rehabilitation program itself may be the primary driver of improvement, and a single PRP injection may not add meaningful benefit for this condition. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/31038979

MENISCAL TEARS

  1. Sánchez et al. (2023) — Largest PRP Study for Meniscal Tears: Intrameniscal + Intra-Articular PRP (392 Patients)

This large study of 392 patients with meniscal tears found that a combination of PRP injected directly into the torn meniscus and into the joint achieved a remarkable 90.3% survival rate (meaning only 10% eventually needed surgery) with a mean survival time of over 4.5 years. All patient-reported outcome scores improved significantly, and the treatment was most effective for horizontal tears and less effective when cartilage damage was also present. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37302993

  1. Xie et al. (2022) — Meta-Analysis of 8 RCTs: PRP Augmentation of Meniscal Repair Surgery (431 Patients)

This meta-analysis found that adding PRP during meniscal repair surgery significantly improved pain scores and knee function (Lysholm score) compared to surgery alone, with no serious adverse events reported. While the healing rate trended toward improvement with PRP, it did not reach statistical significance, suggesting PRP enhances the recovery experience even if its effect on structural healing needs further study. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35984172

SAFETY

  1. Nakagawa et al. (2026) — Safety Meta-Analysis of 32 RCTs: PRP Adverse Events for Knee OA (1,268 PRP-Treated Knees)

This safety-focused meta-analysis of 32 randomized trials found that PRP injections caused only mild, temporary side effects — most commonly mild knee pain and swelling (10.6%) that resolved without treatment — and no serious adverse events were reported in any study. Leukocyte-poor PRP had a safety profile identical to hyaluronic acid, while leukocyte-rich PRP caused slightly more temporary swelling, confirming PRP’s excellent overall safety. 

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42101047

Appointments and Questions

MFAT Clinical Research

KNEE OSTEOARTHRITIS

  1. Richter et al. (2025) — Randomized Controlled Trial: MFAT vs. Corticosteroid vs. Saline for Knee OA

This randomized controlled trial of 75 patients found that a single MFAT injection provided significantly better and longer-lasting pain relief than both corticosteroid and saline placebo injections, with improvements sustained through 1 year — while corticosteroid benefits faded after just 6 weeks. The study suggests MFAT may be a viable alternative for patients with knee arthritis who fall into the “treatment gap” between conservative care and surgery. 

[1]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39243998

  1. Zaffagnini et al. (2022) — Level I RCT: MFAT vs. PRP for Knee OA at 2-Year Follow-Up

This Level I randomized trial of 118 patients found that a single MFAT injection provided clinically significant improvements in pain and function lasting up to 2 years, performing comparably to PRP with no disease progression on MRI. Notably, patients with moderate-to-severe arthritis who received MFAT were significantly more likely to achieve a meaningful clinical improvement than those who received PRP (75% vs. 35%). 

[2]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35984721

  1. Gobbi et al. (2021) — Multi-Center International Study: MFAT in Elderly Patients with Knee OA

This multi-center international study of 75 elderly patients (average age 70) with KL grade 2–4 knee arthritis found that a single MFAT injection led to significant improvements in pain, function, and quality of life sustained through 2 years, with an 88% success rate even in patients with advanced disease. The study provides evidence that MFAT is a safe and effective option for older patients who may not be ideal surgical candidates. 

[3]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33649891

  1. Ulivi et al. (2023) — RCT: MFAT + Arthroscopic Debridement vs. Debridement Alone for Knee OA

This randomized trial of 78 patients with severe knee arthritis (KL grade 3–4) found that adding MFAT to arthroscopic debridement significantly improved functional scores and MRI cartilage appearance compared to debridement alone, with benefits lasting over 2 years. The study supports the use of MFAT as an add-on treatment during knee arthroscopy to enhance outcomes in advanced arthritis. 

[4]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36040510

  1. De Groote et al. (2025) — MFAT for Advanced Knee OA Including KL Grade IV

This longitudinal study of 39 patients with moderate-to-severe knee arthritis (KL grade II–IV) found that a single MFAT injection produced clinically meaningful improvements in all pain and function scores, peaking at 6 months and remaining above baseline at 1 year — including in patients with the most advanced disease. Only minor, self-limiting joint swelling was reported in 18% of cases, with no serious adverse events. 

[5]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41010772

SYSTEMATIC REVIEWS & META-ANALYSES — KNEE OA

  1. Park et al. (2025) — Meta-Analysis: MFAT vs. PRP for Knee OA (RCTs Only)

This meta-analysis of 6 randomized controlled trials found that both MFAT and PRP provided clinically meaningful pain relief and functional improvement for up to 24 months, with MFAT showing a small but statistically significant advantage over PRP at the 6-month mark. Both treatments were equally safe, supporting MFAT as a viable alternative to PRP for knee arthritis. 

[6]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/40990578

  1. Hohmann et al. (2025) — Systematic Review of 21 Studies: MFAT for Knee OA

This comprehensive systematic review of 21 clinical studies found that MFAT injections consistently improved pain scores (from 5.2 to 3.2 on VAS) and all KOOS subscores at 6 and 12 months, demonstrating comparable effectiveness to other orthobiologic injections including PRP and BMAC. The review confirms MFAT is effective but notes that moderate study quality warrants cautious interpretation. 

[7]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/38467171

  1. Hohmann et al. (2025) — Meta-Analysis: MFAT vs. PRP and BMAC for Knee OA

This meta-analysis directly comparing MFAT to PRP and BMAC found no statistically significant differences in pain or function scores at 3, 6, or 12 months, confirming that MFAT performs comparably to other orthobiologic treatments for knee arthritis. The findings suggest that the choice between MFAT, PRP, and BMAC may come down to practical considerations such as availability and patient preference rather than clinical superiority. 

[8]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39751667

  1. Batista et al. (2026) — Systematic Review of 19 RCTs: Adipose-Derived Cell Therapies for Knee OA

This systematic review of 19 randomized controlled trials found that all adipose-derived therapies (including MFAT) are safe and provide meaningful pain relief and functional improvement, with no serious treatment-related adverse events reported across any study. MFAT trials showed symptomatic benefits comparable to established injectable therapies, though structural cartilage changes on MRI were limited. 

[9]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/42100287

HIP OSTEOARTHRITIS

  1. Natali et al. (2023) — 3-Year Follow-Up: MFAT for Hip OA

This study of 55 patients with early-to-moderate hip arthritis found that over half (51%) experienced lasting benefit from a single MFAT injection with no need for further treatment at 3 years, while those who did eventually need surgery were able to delay hip replacement by an average of 16 months. The best results were seen in patients with mild-to-moderate disease (Oxford Hip Score 30–48), identifying the ideal candidates for this treatment. 

[10]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36302901

  1. Heidari et al. (2022) — MFAT vs. MFAT + PRP for Hip OA (147 Patients)

This observational study of 147 patients with hip arthritis (grades 1–4) found that both MFAT alone and MFAT combined with PRP produced significant improvements in pain and hip function scores, with over 60% of patients achieving a pain reduction of 20 points or more on the VAS scale. The combination of MFAT + PRP may be particularly useful for patients with low body fat where obtaining sufficient MFAT alone is challenging. 

[11]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35207329

ROTATOR CUFF

  1. Randelli et al. (2022) — Level II RCT: MFAT Augmentation of Arthroscopic Rotator Cuff Repair

This randomized controlled trial of 44 patients found that adding MFAT injection during arthroscopic rotator cuff surgery led to significantly better shoulder function scores (Constant-Murley) at 6 months compared to surgery alone, with no increase in complications or retear rates. The study was the first RCT to demonstrate that MFAT is a safe and effective addition to rotator cuff repair surgery. 

[12]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/35302901

  1. Lundeen et al. (2023) — Adipose-Derived Cells vs. Corticosteroid for Partial Rotator Cuff Tears (3+ Year Follow-Up)

This long-term follow-up study found that patients with partial rotator cuff tears who received a single injection of adipose-derived regenerative cells had significantly better shoulder function scores (ASES) than those who received a corticosteroid injection, with benefits sustained beyond 3 years. MRI imaging at 6 months showed visible evidence of the cells actively promoting tissue healing, and no safety concerns were identified. 

[13]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37935850

  1. Ferrell et al. (2023) — Case Report: MFAT for Full-Thickness Supraspinatus Tear

A 70-year-old woman with a full-thickness rotator cuff tear that had not improved with conservative treatment received an MFAT injection and experienced progressive improvements in pain and function, with both ultrasound and MRI showing evidence of tendon healing over time. This case demonstrates that MFAT may offer a non-surgical option for certain non-retracted, full-thickness rotator cuff tears. 

[14]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/37727974

  1. Hogaboom et al. (2021) — Pilot Study: MFAT for Refractory Rotator Cuff Disease in Wheelchair Users

This pilot study of 10 wheelchair users with chronic spinal cord injuries and shoulder pain from rotator cuff disease found that ultrasound-guided MFAT injections produced significant improvements in pain and function lasting through 12 months, with nearly 78% of patients achieving clinically meaningful pain reduction. The study highlights MFAT as a potentially valuable option for patients with limited surgical alternatives. 

[15]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33830898

TENDINOPATHY & TENDON TEARS

  1. Usuelli et al. (2018) — Level I RCT: Adipose SVF vs. PRP for Achilles Tendinopathy

This randomized controlled trial of 44 patients found that both adipose-derived stromal vascular fraction (SVF) and PRP injections significantly improved pain and function in chronic Achilles tendon problems, but patients receiving SVF recovered significantly faster in the first month. The study suggests adipose-derived treatment may be preferred for patients who need an earlier return to daily activities or sport. 

[16]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/28251260

  1. Iuso et al. (2022) — Case Report: MFAT for Intrasubstance Achilles Tendon Tear

A patient with a chronic partial Achilles tendon tear that had failed all other treatments received an MFAT injection and was able to return to full activity within 4 weeks, remaining completely pain-free at 6 months with ultrasound confirmation of progressive tendon healing. This case highlights the potential of MFAT as a regenerative treatment for partial Achilles tendon tears that have not responded to conventional therapy. 

[17]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/36068962

  1. Siddiqui et al. (2024) — Case Report: MFAT for Full-Thickness Common Extensor Tendon Tear (Tennis Elbow)

A 56-year-old man with a full-thickness tear and retraction of his common extensor tendon (severe tennis elbow) — caused by a prior corticosteroid injection — received an MFAT injection and showed complete tendon bridging and remodeling on ultrasound by 15 weeks, with full resolution of the retraction. This case presents a promising non-surgical option for patients with full-thickness tendon tears who wish to avoid or cannot undergo surgery. 

[18]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39387455

COMPREHENSIVE REVIEWS & SAFETY

  1. Parmar et al. (2026) — Comprehensive Review: MFAT in Orthopedic Regeneration

This comprehensive narrative review found that MFAT (most commonly processed via the Lipogems system) has demonstrated consistent improvements in pain and function across multiple joint conditions, with a favorable safety profile and procedural simplicity that makes it an attractive point-of-care orthobiologic. The review notes that MFAT performs comparably to PRP and BMAC rather than showing clear superiority, and calls for larger, standardized trials to define its long-term role. 

[19]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/41862417

  1. Varone et al. (2024) — Safety Study: MFAT Harvesting and Injection Under Local Anesthesia

This safety-focused case series of 34 patients confirmed that harvesting adipose tissue from the abdomen and injecting MFAT into the knee can be safely performed under local anesthesia alone (without sedation), with only minor bruising (77%) and mild temporary discomfort at the harvest and injection sites — and no major adverse events. The study supports MFAT as a safe, office-based procedure that does not require general anesthesia. 

[20]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/39631149

  1. Zhao et al. (2021) — Network Meta-Analysis: Adipose MSCs, PRP, BMAC, and HA for Knee OA

This large network meta-analysis of 43 randomized controlled trials found that adipose-derived mesenchymal stem cells provided the best pain relief at both 6 and 12 months compared to PRP, BMAC, hyaluronic acid, and placebo, and were the only treatment to show significant pain improvement over placebo at 1 year. The study positions adipose-derived therapies as among the most effective biologic options for knee arthritis pain. 

[21]

🔗 PubMed: https://pubmed.ncbi.nlm.nih.gov/33713757

Radiofrequency Ablation Clinical Research

Radiofrequency ablation (RFA) is a minimally invasive, non-surgical treatment that uses heat to quiet the small nerves that carry pain signals from arthritic joints and the spine. Our protocols are grounded in the best available peer-reviewed research. Below are landmark studies behind each of the treatments we offer.

—

Lumbar (Low Back) RFA

Conger et al. (2020) — Medial Branch RFA in Carefully Selected Patients

Eighty-five patients with chronic low back pain from the facet joints were selected using two confirmatory nerve blocks before treatment. After RFA, roughly two-thirds of patients (63% at 6–12 months and 66% at 12–24 months) had at least a 50% reduction in pain, and more than half felt “much improved” or better. The key lesson: when patients are carefully selected, RFA delivers meaningful, long-lasting back pain relief.

—

Cervical (Neck) RFA

van Eerd et al. (2021) — Sham-Controlled Trial of Cervical Facet RFA

In this rigorous double-blind study, 76 patients with chronic neck pain received either real RFA or a placebo procedure. The standout finding was durability: relief lasted a median of 42 months in the RFA group versus only 12 months in the comparison group. RFA provided significantly longer-lasting neck pain relief.

—

Sacroiliac (SI) Joint RFA

Cohen et al. (2024) — Cooled RFA vs. Standard Care (210 Patients)

This large multicenter trial compared cooled RFA to standard medical management (medications, injections, physical therapy) in 210 patients with SI joint pain. At 3 months, 52% of the RFA group were responders compared to just 4% of those on standard care, with better pain, function, and quality-of-life scores — benefits that held up at 12-month follow-up. This is the largest study of its kind for SI joint pain.

—

Basivertebral Nerve Ablation (BVNA / INTRACEPT)

Fischgrund et al. (2018) — Pivotal Sham-Controlled Trial (225 Patients)

This FDA-cleared pivotal trial treated a specific type of chronic low back pain (identified by “Modic changes” on MRI) by targeting a nerve inside the vertebra itself. Compared to a placebo procedure, 76% of treated patients achieved a meaningful improvement in function versus 55% with placebo. Long-term follow-up of this approach has shown relief lasting five years or more, making it one of the most durable options for this type of back pain.

—

Genicular Nerve RFA (Knee Osteoarthritis)

Choi et al. (2011) — Conventional Radiofrequency Ablation vs. Sham: The First Randomized Trial of Genicular Nerve RFA
This was the original randomized, double-blind, sham-controlled trial that introduced genicular nerve RFA. Thirty-eight patients with chronic, severe knee osteoarthritis pain that had not responded to conservative care were randomly assigned to receive either conventional thermal RFA of three sensory nerves around the knee (the superomedial, superolateral, and inferomedial genicular nerves) or a placebo (sham) procedure. The RFA group had significantly lower pain scores than the sham group at both 4 and 12 weeks, along with meaningful improvement in knee function, and no serious complications occurred. This landmark study established that heating the small sensory nerves of the knee can safely reduce arthritis pain, and it defined the initial nerve targets which have been refined over the 15 years since the study. 
—

Every treatment described here is supported by peer-reviewed clinical research. Individual results vary, and a consultation is needed to determine whether RFA is appropriate for your specific condition.

Orthobiologics for the Spine Clinical Research

Our clinical protocols are rooted in evidence-based medicine. We utilize peer-reviewed data to guide our patient selection and treatment strategies, focusing on the safety, functional outcomes, and biological mechanisms of orthobiologic therapies.
 
I. Intradiscal Platelet-Rich Plasma (PRP) for intervertebral disc pathology
Intradiscal PRP targets the intervertebral disc itself as the primary pain generator, addressing the underlying degenerative process rather than only the downstream inflammation of the nerve root. The rationale rests on a fundamental biological problem: the intervertebral disc is the largest avascular structure in the body, and this lack of blood supply leaves the degenerating disc with a very limited capacity for self-repair. By injecting a concentrated platelet preparation directly into the nucleus pulposus, intradiscal PRP is designed to deliver a supraphysiologic dose of growth factors — including TGF-β1, PDGF, IGF, VEGF, and EGF —  where the native healing response is deficient. These factors act through a dual mechanism: an anabolic effect that stimulates disc cell proliferation and extracellular matrix synthesis, and an anti-inflammatory, anti-catabolic effect that downregulates degrading enzymes and pro-inflammatory cytokines that drive both disc breakdown and pain. Preclinical models support this biology, with PRP shown to restore disc height, improve MRI T2 signal, and slow histologic degeneration, while human data continue to evolve. Clinically, this translates into the durability that distinguishes intradiscal PRP from anti-inflammatory-only approaches — a single injection has produced sustained pain and functional improvement in the majority of appropriately selected patients as far out as 5–9 years, consistent with a disease-modifying rather than purely palliative effect. Because the procedure uses the patient’s own blood and involves no corticosteroid, it also avoids the systemic effects and cumulative-dose limitations that constrain repeat steroid injections.
 
Sentinel & Long-Term Studies
Tuakli-Wosornu et al. (2016) — Intradiscal PRP vs. Control Injection: Randomized Controlled Trial for Discogenic Low Back Pain
This landmark double-blind, randomized controlled trial treated 47 patients with chronic moderate-to-severe discogenic low back pain that had not responded to conservative treatment — 29 received intradiscal PRP and 18 received a control injection of contrast agent alone. Patients who received PRP showed significant improvements in pain, function, and patient satisfaction compared to controls by 8 weeks, and those improvements in functional scores were maintained for at least 1 year. This remains the foundational RCT for intradiscal PRP therapy. PubMed: https://pubmed.ncbi.nlm.nih.gov/26972847
Cheng et al. (2019) — 5-to-9-Year Follow-Up of the Tuakli-Wosornu RCT
This long-term follow-up study re-evaluated 21 of the original 29 PRP-treated patients from the Tuakli-Wosornu trial at 5 to 9 years after their single intradiscal PRP injection. Seventy-one percent of patients were classified as treatment successes, demonstrating sustained and clinically significant improvements in both pain and function — while the remaining 29% eventually required spinal surgery. This is the longest follow-up data available for intradiscal PRP and strongly suggests that a single injection can provide durable, multi-year relief for the majority of appropriately selected patients. PubMed: https://pubmed.ncbi.nlm.nih.gov/31152576
Comparative & Mechanistic Studies
Akeda et al. (2022) — Intradiscal PRP vs. Corticosteroid: Double-Blind Randomized Trial
This double-blind randomized trial compared intradiscal PRP releasate to corticosteroid injection in 16 patients with discogenic low back pain. Both groups achieved clinically significant pain relief that was equivalent at 8 weeks, but the PRP group showed significantly better disability scores at 26 weeks and superior walking ability at 4 and 8 weeks. Disc height and MRI grading remained stable, and PRP caused no clinically important adverse events through 60 weeks of follow-up. The study suggests PRP provides pain relief comparable to steroid but with more durable functional improvement. PubMed: https://pubmed.ncbi.nlm.nih.gov/35053999
Lutz et al. (2022) — Higher-Concentration PRP Yields Better Outcomes for Lumbar Disc Pain
This study of 37 patients who received intradiscal injections of higher-concentration PRP (>10× baseline platelet count) found significant improvements in pain and function at an average of 18 months. Compared to a historical cohort that received lower-concentration PRP (<5×), the higher-concentration group had significantly greater pain reduction, better functional improvement, and a higher satisfaction rate (81% vs. 55%). These findings suggest that optimizing platelet concentration is an important factor in maximizing treatment outcomes. PubMed: https://pubmed.ncbi.nlm.nih.gov/35344055
Prospective Clinical Trials
Zhang et al. (2022) — Single Intradiscal PRP Injection: 48-Week Prospective Trial
This prospective trial treated 31 patients with chronic discogenic low back pain with a single intradiscal PRP injection and followed them for 48 weeks. Pain and lumbar function improved significantly at every time point compared to baseline, with 71% of patients classified as treatment successes. One patient developed discitis at two weeks post-injection, highlighting the importance of sterile technique. The study supports the durability of a single PRP injection for nearly a full year. PubMed: https://pubmed.ncbi.nlm.nih.gov/35378903
Pan et al. (2026) — Intradiscal PRP with Quantitative MRI: Prospective Cohort Study
This prospective cohort study of 45 patients (29 completing follow-up) evaluated both clinical outcomes and quantitative MRI changes after intradiscal PRP injection. At 6 months, 79.3% of patients achieved the composite clinically meaningful improvement threshold (≥30% reduction in both pain and disability scores). Notably, MRI showed a significant decrease in vertebral marrow fat fraction adjacent to the treated disc — a finding that correlated with symptom improvement — suggesting PRP may exert an early biological effect on the peridiscal metabolic environment. No treatment-related complications were observed. PubMed: https://pubmed.ncbi.nlm.nih.gov/41876737
Intradiscal PRP vs. BMAC / Stem Cell Therapies — Comparative Evidence
Navani et al. (2024) — PRP vs. BMC vs. Placebo: The Only Head-to-Head Randomized Controlled Trial
This is the only human lumbar disc study that directly compares both PRP and bone marrow concentrate (BMC) to placebo in the same trial. Forty patients with chronic discogenic low back pain were randomized to receive intradiscal PRP, intradiscal BMC, or a saline trigger point injection (placebo), with follow-up at 1, 3, 6, and 12 months. Both PRP and BMC produced statistically significant improvements in pain and function compared to baseline — and all placebo patients failed to achieve 50% pain relief and crossed over to an active treatment arm. Importantly, no patients in either active group required hospitalization, emergency visits, or spine surgery through 12 months, and no adverse effects were reported. The study was not powered to detect differences between PRP and BMC, but both were clearly superior to placebo. PubMed: https://pubmed.ncbi.nlm.nih.gov/38285032
 
II. Epidural PRP — A Complementary Treatment Approach
Epidural PRP represents a complementary approach to intradiscal PRP, targeting a different pain generator — the inflamed nerve root and epidural space rather than the disc itself.  A recent systematic review highlighted several advantages of the epidural route, including that it avoids the risk of discitis associated with intradiscal needle penetration, enables simultaneous treatment of multiple affected levels, and is particularly relevant in older patients or those with advanced disc degeneration and narrowed disc spaces where intradiscal injections may be technically difficult and biologically less effective. Across 5 RCTs and 310 patients, epidural PRP has provided comparable or superior pain relief to epidural steroid, with a consistent pattern in which steroids work faster (1–4 weeks) but PRP delivers more durable benefit (3–6+ months), and it does so with no increase in adverse events while avoiding the systemic corticosteroid effects — adrenal suppression, hyperglycemia, and bone density loss — that limit repeat steroid injections. Beyond reducing inflammation, PRP may also promote nerve repair, and this is an area of ongoing research. Most importantly, when combined with intradiscal PRP (as in the Anitua et al. PRGF protocol summarized below), epidural PRP addresses both the structural disc pathology and the secondary radicular inflammation simultaneously — a combined intradiscal plus epidural strategy that represents the most comprehensive treatment approach and has produced the highest reported success rate in the literature (87.5%).
Randomized Controlled Trials
Wongjarupong et al. (2023) — Transforaminal Epidural PRP vs. Triamcinolone: RCT for Lumbar Disc Herniation
This randomized controlled trial compared transforaminal epidural PRP to triamcinolone in 30 patients with single-level lumbar disc herniation. PRP was prepared using a double-spin protocol from 24 mL of venous blood. Patients treated with PRP showed statistically and clinically significant reductions in leg pain at 6, 12, and 24 weeks, and in disability at 24 weeks — with PRP yielding superior results to triamcinolone at these time points. No adverse events occurred in either group. The authors concluded that noncommercial epidural double-spin PRP yielded superior results to triamcinolone and recommended the procedure for treating single-level lumbar disc herniation. PubMed: https://pubmed.ncbi.nlm.nih.gov/37118707 
Ruiz-Lopez & Tsai (2020) — Caudal Epidural LR-PRP vs. Corticosteroid: Double-Blind RCT
This double-blind randomized controlled trial compared leucocyte-rich PRP (LR-PRP, prepared from 60 mL autologous blood) to triamcinolone 60 mg via fluoroscopically guided caudal epidural injection in 50 patients with complex chronic degenerative spinal pain. Corticosteroid produced a significantly lower VAS score at 1 month, but PRP was superior at 3 and 6 months. At 6 months, the PRP group showed significant improvement in all SF-36 domains, while the steroid group improved in only the bodily pain domain. No complications or adverse effects were reported in either group. The study demonstrated that PRP provides a longer-lasting pain-relieving effect and greater quality-of-life improvement than corticosteroid. PubMed: https://pubmed.ncbi.nlm.nih.gov/32255266 
Meta-Analyses & Systematic Reviews
Zhang et al. (2026) — European Spine Journal Systematic Review: Epidural PRP for Radiculopathy
This comprehensive systematic review of 13 RCTs across all spinal biologic therapies found that for lumbar radiculopathy specifically, four trials showed that corticosteroids provided faster early relief, but PRP produced significantly greater improvement at 3–6 months, with higher proportions of patients achieving clinically meaningful pain and ODI reduction. This pattern — steroids faster early, PRP more durable later — was the most consistent finding across the epidural PRP literature. PubMed: https://pubmed.ncbi.nlm.nih.gov/42141193 
Marchesini et al. (2026) — Regenerative Medicine vs. Steroids: Comprehensive Review
This comprehensive review across all musculoskeletal and spinal pain indications found a consistent pattern: corticosteroids showed an early advantage at 2–8 weeks, whereas PRP demonstrated superior pain and functional outcomes at ≥3–6 months. For epidural approaches specifically, PRP was non-inferior in the short term and in some studies superior by 24 weeks. Both strategies were generally safe, although local and systemic adverse events were more frequent with corticosteroids. The authors proposed that conceptualizing PRP as primarily an immuno-inflammatory modulator rather than strictly “regenerative” may better explain its longer-term effects. PubMed: https://pubmed.ncbi.nlm.nih.gov/42089640 
 
III. Combined Intradiscal + Epidural PRP Protocol
Anitua et al. (2023) — Combined Intradiscal and Epidural PRGF: Prospective Study
This prospective study treated 32 patients with chronic cervical and lumbar pain using a combined protocol of 2–3 series of intradiscal and epidural PRGF (leukocyte-free PRP) infiltrations performed under fluoroscopic guidance. At 6 months, 87.5% of patients achieved clinically significant pain reduction (>30% improvement), with statistically significant improvements in NRS, ODI, and COMI scores at every time point (all P < 0.001). This combined approach — treating both the disc and the epidural space in the same session — represents the most comprehensive PRP protocol studied for spinal pain and produced the highest success rate in the literature. PubMed: https://pubmed.ncbi.nlm.nih.gov/37847927 
 
IV. Facet Joint PRP
The facet joints (small joints at the back of the spine) and the sacroiliac (SI) joints (where the spine meets the pelvis) are two of the most common sources of chronic low back pain. Concentrated PRP from your own blood helps repair and strengthen these worn-down joints — in atempt to treat the underlying problem rather than just quieting the pain for a short time. 
A clear pattern shows up in the research: steroid shots work faster (best relief around 1 month), but PRP lasts longer, giving better pain relief at 3 to 6 months. This was confirmed in a large analysis of 392 patients across 10 studies. SI joint PRP is backed by several high-quality trials, and national pain guidelines list regenerative injections as a reasonable option when physical therapy and steroid shots haven’t worked. Facet joint PRP has moderate-quality evidence supporting its use — stronger than the evidence for stem cell injections in these joints.
PRP has been very safe across studies, with no serious treatment-related complications and fewer whole-body side effects than repeated steroid shots. The main caveat: while results are promising, larger studies are still needed to confirm exactly how well and how long it works.
Wu et al. (2017) — PRP vs. Steroid for Lumbar Facet Joint Syndrome: Randomized Controlled Trial
This randomized trial split 46 patients with lumbar facet joint pain into two groups — one received PRP injected into the facet joints, the other received the standard combination of local anesthetic and steroid. Both treatments worked well early on, but their paths diverged over time: the steroid group’s satisfaction and success rates peaked at 1 month (80% and 85%) and then fell sharply by 6 months (50% and 20%), while the PRP group’s results kept improving over the full 6 months. Both were safe with no treatment-related complications. The takeaway is that PRP and steroid are both effective for facet joint pain, but PRP provides longer-lasting relief. PubMed: https://pubmed.ncbi.nlm.nih.gov/27989008 [1]
Manchikanti et al. (2025) — Regenerative Medicine for Facet Joint Pain: Systematic Review
This systematic review pooled 4 randomized trials and 6 observational studies of PRP and stem cells for axial spine pain coming from the facet joints. Across the studies, PRP consistently improved pain, physical function, and quality of life. Using formal GRADE evidence grading, the authors rated the evidence for facet joint PRP as Level II (moderate) with a moderate strength of recommendation — stronger than the evidence for stem cells, which received only a weak recommendation. The review supports facet PRP as a reasonable option, while noting that larger high-quality trials are still needed. PubMed: https://pubmed.ncbi.nlm.nih.gov/40085275 [2]
VI. Sacroiliac (SI) Joint PRP
Singla et al. (2017) — PRP vs. Steroid for SI Joint Pain: Randomized Controlled Trial
This randomized trial treated 40 patients with sacroiliac joint pain — 20 received a single ultrasound-guided injection of PRP, and 20 received a steroid (methylprednisolone) injection. At 3 months, a striking 90% of the PRP group achieved at least 50% pain relief, compared to only 25% of the steroid group, with significantly lower pain scores in the PRP group at both 6 weeks and 3 months. This is the most frequently cited randomized trial supporting SI joint PRP and shows a clear durability advantage over steroids.  PubMed (via ASPN guideline summary) [3-4]
Peckham et al. (2026) — CT-Guided PRP vs. Steroid for SI Joint Pain: Randomized Controlled Trial
This single-blinded randomized trial enrolled 44 patients with sacroiliac joint pain confirmed by a diagnostic anesthetic block, then randomized them to CT-guided PRP or a steroid/anesthetic injection. Both groups improved significantly. Consistent with the broader PRP literature, steroid produced greater early relief, while PRP produced more sustained improvement — with a trend toward more PRP patients achieving ≥50% pain relief at 3 months (60% vs. 35%) and greater gains in disability and physical quality of life. The authors concluded PRP is a viable, safe alternative to steroids for chronic SI joint pain. PubMed: https://pubmed.ncbi.nlm.nih.gov/41876223 
Combined Facet + SI Joint Evidence
Alatefi et al. (2026) — PRP vs. Steroid for Facet and SI Joint Pain: Meta-Analysis
This meta-analysis pooled 10 randomized and quasi-randomized trials (6 facet, 4 SI joint) enrolling 392 patients. At 1 month, PRP and steroid were statistically similar. But by 3 months PRP significantly outperformed steroid (pain reduction 1.32 points greater on a 10-point scale), and this superiority persisted at 6 months (1.70 points greater) — with consistent benefit across both the facet and SI joint subgroups. The authors concluded PRP is a promising biologic offering more durable medium- and long-term pain relief than steroids for both joint types, though they cautioned the certainty of evidence remains limited.  PubMed: https://pubmed.ncbi.nlm.nih.gov/42296329

Clinical Guidance & Regulatory Standards

We follow the most rigorous standards for “minimal manipulation” and “homologous use” as outlined by the FDA. Our procedures are performed in-office using sterile, closed-system technologies to ensure patient safety and tissue integrity.

Research Integrity: We encourage patients to review these studies to better understand the biological basis for the therapies we offer. While this research is promising, it is important to discuss your specific imaging and symptoms with a specialist to determine your candidacy for treatment.

Appointments and Questions